Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors
View/ Open
Author
López-Camacho, César
Abbink, Peter
Dejnirattisai, Wanwisa
Boyd, Michael
Badamchi-Zadeh, Alex
Wallace, Zoë R.
Doig, Jennifer
Velazquez, Ricardo Sanchez
Neto, Roberto Dias Lins
Coelho, Danilo F.
Kim, Young Chan
Donald, Claire L.
Owsianka, Ania
De Lorenzo, Giuditta
Kohl, Alain
Gilbert, Sarah C.
Dorrell, Lucy
Mongkolsapaya, Juthathip
Patel, Arvind H.
Screaton, Gavin R.
Hill, Adrian V. S.
Reyes-Sandoval, Arturo
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1038/s41467-018-04859-5Metadata
Show full item recordCitation
López-Camacho, C., P. Abbink, R. A. Larocca, W. Dejnirattisai, M. Boyd, A. Badamchi-Zadeh, Z. R. Wallace, et al. 2018. “Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors.” Nature Communications 9 (1): 2441. doi:10.1038/s41467-018-04859-5. http://dx.doi.org/10.1038/s41467-018-04859-5.Abstract
Zika virus (ZIKV) emerged on a global scale and no licensed vaccine ensures long-lasting anti-ZIKV immunity. Here we report the design and comparative evaluation of four replication-deficient chimpanzee adenoviral (ChAdOx1) ZIKV vaccine candidates comprising the addition or deletion of precursor membrane (prM) and envelope, with or without its transmembrane domain (TM). A single, non-adjuvanted vaccination of ChAdOx1 ZIKV vaccines elicits suitable levels of protective responses in mice challenged with ZIKV. ChAdOx1 prME ∆TM encoding prM and envelope without TM provides 100% protection, as well as long-lasting anti-envelope immune responses and no evidence of in vitro antibody-dependent enhancement to dengue virus. Deletion of prM and addition of TM reduces protective efficacy and yields lower anti-envelope responses. Our finding that immunity against ZIKV can be enhanced by modulating antigen membrane anchoring highlights important parameters in the design of viral vectored ZIKV vaccines to support further clinical assessments.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015009/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:37298439
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)